Advertisement

Acute Respiratory Failure in the Oncologic Patient: New Era, New Issues

  • B. L. Ferreyro
  • L. MunshiEmail author
Chapter
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM)

Abstract

Recent decades have seen an increase in the number of patients living with cancer. This trend has resulted in an increase in intensive care unit (ICU) utilization across this population [1]. Acute respiratory failure is the most frequent medical complication leading to critical illness in oncologic patients [2–4]. Historically, there had been a reluctance to admit cancer patients to the ICU given their poor outcomes, particularly in the setting of hematologic malignancy and invasive mechanical ventilation [5]. ICU treatment limitations or refusal of admission was advocated [6]. Major advances in oncologic care, critical care and more meticulous attention to where the conditions overlap, have resulted in marked improvement in short-term survival in this population [1, 7, 8]. Despite these major advances, acute respiratory failure in this population remains complex with unique challenges surrounding diagnosis and management compared to the general ICU population. This chapter provides a comprehensive overview of acute respiratory failure in the oncologic population and highlights specific considerations for the intensivist. We will focus on the important differences between the immunocompromised oncologic patient and general intensive care population, the spectrum of causes of acute respiratory failure with a specific focus on toxicities related to newer cancer therapies, diagnostic approach, management and an up-to-date overview of prognosis.

References

  1. 1.
    Taccone F, Artigas A, Sprung C, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13:R15.CrossRefGoogle Scholar
  2. 2.
    Pastores SM. Acute respiratory failure in critically ill patients with cancer. Diagnosis and management. Crit Care Clin. 2001;17:623–46.CrossRefGoogle Scholar
  3. 3.
    Mokart D, Etienne A, Esterni B, et al. Critically ill cancer patients in the intensive care unit: short-term outcome and 1-year mortality. Acta Anaesthesiol Scand. 2011;56:178–89.CrossRefGoogle Scholar
  4. 4.
    Azoulay E, Pickkers P, Soares M, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017;316:1–12.Google Scholar
  5. 5.
    Kress JP, Christenson J, Pohlman AS, et al. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med. 1999;160:1957–61.CrossRefGoogle Scholar
  6. 6.
    Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Guidelines for intensive care unit admission, discharge and triage. Crit Care Med. 1999;27:633–8.CrossRefGoogle Scholar
  7. 7.
    Azoulay E, Mokart D, Pène F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013;31:2810–22.CrossRefGoogle Scholar
  8. 8.
    Schellongowski P, Sperr W, Wohlfarth P, et al. Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review. ESMO Open. 2016;201:1.Google Scholar
  9. 9.
    Gutierrez C, McEvoy C, Mead E, et al. Management of the critically ill adult chimeric antigen receptor-t cell therapy patient. Crit Care Med. 2018;46:1402–10.CrossRefGoogle Scholar
  10. 10.
    June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.CrossRefGoogle Scholar
  11. 11.
    Azoulay E, Roux A, Vincent F, et al. A multivariable prediction model for Pneumocystis jirovecii pneumonia in hematology patients with acute respiratory failure. Am J Respir Crit Care Med. 2018;198:1519–26.Google Scholar
  12. 12.
    Dhokarh R, Li G, Schmickl CN, et al. Drug-associated acute lung injury. Chest. 2012;142:845–50.CrossRefGoogle Scholar
  13. 13.
    Reinert T, Baldotto CS, Nunes FAP, et al. Bleomycin induced lung injury. J Cancer Res. 2013;2013:1–9.CrossRefGoogle Scholar
  14. 14.
    Wills B, Brahmer JR, Naidoo J. Treatment of complications from immune checkpoint inhibition in patients with lung cancer. Curr Treat Options Oncol. 2018;19:1–21.Google Scholar
  15. 15.
    Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68.CrossRefGoogle Scholar
  16. 16.
    Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.CrossRefGoogle Scholar
  17. 17.
    Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607–16.CrossRefGoogle Scholar
  18. 18.
    Postow M, Sidlow R, Hellmann D. Immune related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.CrossRefGoogle Scholar
  19. 19.
    Mirrakhimov AE, Voore P, Khan M, et al. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4:130–8.CrossRefGoogle Scholar
  20. 20.
    Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54.CrossRefGoogle Scholar
  21. 21.
    Macaluso A, Genova S, Maringhini S, et al. Acute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia. Pediatr Rep. 2015;7:5760–2.CrossRefGoogle Scholar
  22. 22.
    Bell CM, Stewart TE. Acute respiratory distress syndrome associated with tumour lysis syndrome in leukemia. Can Respir J. 1997;4:48–51.CrossRefGoogle Scholar
  23. 23.
    Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149:1294–301.CrossRefGoogle Scholar
  24. 24.
    Yadav H, Nolan ME, Bohman JK, et al. Epidemiology of acute respiratory distress syndrome following hematopoietic stem cell transplantation. Crit Care Med. 2016;44:1082–90.CrossRefGoogle Scholar
  25. 25.
    Lucena CM, Torres A, Rovira M, et al. Pulmonary complications in hematopoietic SCT: a prospective study. Bone Marrow Transplant. 2014;49:1293–9.CrossRefGoogle Scholar
  26. 26.
    Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183:1262–79.CrossRefGoogle Scholar
  27. 27.
    Azoulay E, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure. Am J Respir Crit Care Med. 2010;182:1038–46.CrossRefGoogle Scholar
  28. 28.
    Deotare U, Merman E, Pincus D, et al. The utility and safety of flexible bronchoscopy in critically ill acute leukemia patients: a retrospective cohort study. Can J Anaesth. 2018;65:272–9.CrossRefGoogle Scholar
  29. 29.
    Cortegiani A, Madotto F, Gregoretti C, et al. Immunocompromised patients with acute respiratory distress syndrome: a secondary analysis of the LUNG SAFE database. Crit Care. 2018;22:157–72.CrossRefGoogle Scholar
  30. 30.
    Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol. 2015;33:501–15.CrossRefGoogle Scholar
  31. 31.
    Pastores S, Goldman D, Shaz D, et al. Characteristics and outcomes of patient with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer. 2018;124:3025–36.CrossRefGoogle Scholar
  32. 32.
    Azoulay E, Lemiale V, Mokart D, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med. 2014;40:1106–14.CrossRefGoogle Scholar
  33. 33.
    Rathi N, Haque S, Nates R, et al. Noninvasive positive pressure ventilation vs invasive mechanical ventilation as first-line therapy for acute hypoxemic respiratory failure in cancer patients. J Crit Care. 2017;39:56–62.CrossRefGoogle Scholar
  34. 34.
    Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates. N Engl J Med. 2001;344:481–7.CrossRefGoogle Scholar
  35. 35.
    Antonellli M, Conti G, Bufi M, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplant: a randomized trial. JAMA. 2000;283:235–41.CrossRefGoogle Scholar
  36. 36.
    Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314:1711–20.CrossRefGoogle Scholar
  37. 37.
    Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185–96.CrossRefGoogle Scholar
  38. 38.
    Frat JP, Ragot S, Girault C, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4:646–53.CrossRefGoogle Scholar
  39. 39.
    Frat JP, Ragot S, Coudroy R, et al. Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy. Crit Care Med. 2018;46:208–15.CrossRefGoogle Scholar
  40. 40.
    Sklar M, Mohamed A, Orchanian-Cheff A, et al. The impact of high flow nasal oxygen in the immunocompromised critically ill: a systematic review and meta-analysis. Respir Care. 2018;63:1555–66.Google Scholar
  41. 41.
    Lloyd-Thomas A, Dhaliwal H, Lister T, et al. Intensive therapy for life-threatening medical complications of hematologic malignancy. Intensive Care Med. 1986;12:317–24.CrossRefGoogle Scholar
  42. 42.
    Bos MM, Bakhshi-Raiez F, Dekker JW, et al. Outcomes of intensive care unit admissions after elective cancer surgery. Eur J Surg Oncol. 2013;39:584–92.CrossRefGoogle Scholar
  43. 43.
    Fisher R, Dangoisse C, Crichton S, et al. Short-term and medium-term survival of critically ill patients with solid tumors admitted to the intensive care unit: a retrospective analysis. BMJ Open. 2016;6:e011363.CrossRefGoogle Scholar
  44. 44.
    Darmon MR, Bernal T, Borges M, et al. Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care. 2012;16:R133.CrossRefGoogle Scholar
  45. 45.
    Van Vliet M, Verburg I, Boogaard M, et al. Trends in admission prevalence, illness severity and survival of hematological patients treated in Dutch intensive care units. Intensive Care Med. 2014;40:1275–84.CrossRefGoogle Scholar
  46. 46.
    Soares M, Bozza F, Azevedo L, et al. Effects of organizational characteristics on outcomes and resource use in patients with cancer admitted to Intensive Care Units. J Clin Oncol. 2016;34:3315–24.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Interdepartmental Division of Critical Care Medicine, Department of Medicine, Mount Sinai Hospital/University Health NetworkUniversity of TorontoTorontoCanada
  2. 2.Internal Medicine Department, Hospital Italiano de Buenos AiresBuenos AiresArgentina

Personalised recommendations